Answers are grounded in this paper and cite their sources.
EDITOR: We report a case of a confirmed anaphylactic reaction to cisatracurium that was initially interpreted as a non-specific anaphylactoid reaction not requiring further allergological investigations. A 62-yr-old female (weight 68 kg) was admitted for cholecystectomy. She had a history of poliomyelitis in childhood, requiring eight consecutive operations on her right leg, and hypertension treated with a β-adrenoceptor blocking agent. She had no history of atopy, allergy, asthma or previous adverse reactions during anaesthesia. Cefazolin 2 g was injected 20 min before induction of anaesthesia without any disturbance of heart rate or arterial pressure (60 beats min−1, 120/70 mmHg). Fentanyl (200 μg), thiopental (500 mg) and cisatracurium (14 mg) were then injected intravenously (i.v.). The trachea was easily intubated and the lungs mechanically ventilated. Anaesthesia was maintained by isoflurane (end-tidal 0.6%) and O2/N2O (50/50). Heart rate and arterial pressure were stable at 65 beats min−1 and 100/70 mmHg, respectively. Five minutes later, a generalized erythema appeared with a rapid but moderate decrease in arterial pressure (80/60 mmHg) and increase in heart rate (70 beats min−1). No wheezing or increase in airway pressure was recorded. End-tidal PCO2 decreased from 5.2 to 3.7 kPa. Symptomatic treatment was started by i.v. phenylephrine injections (four boluses of 6 mg each at 1 min intervals) and circulating volume expansion (1000 mL 0.9% saline) allowing a return of haemodynamic variables to the postinduction values. The erythema lasted approximately 10 min and then progressively disappeared. Haemodynamic fluctuations were initially attributed to induction of anaesthesia, and the erythema to non-specific histamine release following injection of cisatracurium. Further allergological investigations were considered unnecessary. However, colleagues suspected a true anaphylaxis, because non-specific histamine release following cisatracurium injection is uncommon. The operation was then cancelled as recommended, and blood and urine samples were collected in an attempt to establish a diagnosis of anaphylaxis [1]. The patient recovered from anaesthesia without any problems and was extubated 35 min later, and there were no further complications. Results of plasma histamine and tryptase monitoring, immunoglobin E-specific assays as well as skin tests performed 6 weeks later are summarized in Tables 1 and 2. Skin tests were interpreted in comparison with a histamine control (histamine prick-test: IP/OP = 8/20; histamine intradermal test at a 10−2 dilution: 20/65) by an allergologist experienced in performing and interpreting such tests with anaesthetic agents. The patient's skin was considered highly reactive to histamine. Skin tests were then considered positive for mivacurium, cisatracurium and midazolam, and doubtful for fentanyl and thiopental. Based on clinical history, tryptase dosages and skin tests results, a grade II real anaphylactic reaction to cisatracurium was finally recorded both by the pharmacovigilance national institute and the French allergo-anesthesia network members (GERAP).Table 1: Results of biological tests.Table 2: Results of skin tests.Several French surveys focusing on the incidence of peranaesthetic anaphylactic reactions confirmed that neuromuscular blocking agents (NMBAs) were the most incriminated drugs [2-5]. Interestingly, the last survey reported relevant differences among nondepolarizing NMBAs [5]. The incidence was higher with rocuronium and lower with cisatracurium. However, those surveys were based on spontaneous reports, by anaesthetists of suspected anaphylactic reactions, to GERAP. Therefore, under reporting due to misinterpretation of clinical symptoms may distort the results. Since a high percentage of patients presenting with a suspected peroperative anaphylactoid reaction do not have further allergological investigations, results may underestimate the reality [5]. This is particularly suspected in the case of atracurium [6]. Indeed, non-specific histamine release is well described following rapid bolus injections of atracurium so that distinction between a low-grade anaphylactic reaction and a non-specific anaphylactoid reaction is difficult to make clinically. A systematic allergological investigation in case of moderate variations in haemodynamic variables and the appearance of erythema following atracurium injections would be expensive and so is not recommended [1]. However, cisatracurium differs from atracurium regarding non-specific histamine release. Owing to its higher potency, lower doses of cisatracurium are required in order to reach the same depth of curarization, then minimizing histamine release in the clinical setting [7]. Logically, when using cisatracurium, the occurrence of clinical symptoms evoking histamine release should be considered a threat of real anaphylaxis. Patients should then benefit from an allergic 'work up' and instances should be declared both to the pharmacovigilance institute and to GERAP. This may be considered as the main clinical interest of cisatracurium over atracurium. However, as in this current description, assimilation between atracurium and cisatracurium may be made, possibly leading to under reporting of cisatracurium-related potential anaphylactic reactions. On the contrary, since rocuronium is now widely considered in France as an important anaphylactic reaction provider, declarations of even minor clinical events suggesting such a reaction are probably exhaustive. This last attitude is, of course, a good one, but it should be promoted with each agent. If not, one should be particularly suspicious that an artificially lower incidence of real anaphylaxis to cisatracurium compared with other neuromuscular blocking agents exists. Epidemiological surveys such as the French ones are of great importance in providing relative risks of anaphylactic reactions following injections of NMBAs. To improve the veracity of the results, all suspected cases of anaphylaxis should be investigated and declared whatever neuromuscular blocking drug is used. Specifically, all clinical situations evoking histamine release following the injection of cisatracurium should be considered to be potentially real anaphylactic reactions, which facilitates the decision of proceeding or not to an allergologic 'work up' compared with atracurium. However, one can suspect that a parallel is often drawn between those two drugs, so that the incidence of anaphylactic reactions to cisatracurium may be underestimated due to spontaneous under reporting. F. Lagneau B. Corda J.
No takes yet. Share an insight, caveat, or question.
Lagneau et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: